Gene Therapy for Liver Disease

Digestive Diseases

Volumn 16, Issue 1, 1998, Pages 23-37

  Davern II, Timothy J ^a,b   Scharschmidt, Bruce F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adeno associated virus; Adenovirus; Gene therapy; Liposome; Retrovirus; Vector

Indexed keywords

GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HEMOPHILIA B; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; LIVER DISEASE; METHODOLOGY; REVIEW;

GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMOPHILIA B; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIVER DISEASES;

EID: 0031601870     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000016846     Document Type: Review

References (88)

1. Grossman M, Wilson JM: Retroviruses: Delivery vehicle to the liver. Curr Opin Genet Dev 1993;3:110-114.
2. Grossman M, Rader DJ, Muller DW, et al: A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995;1:1148-1154.
3. Grossman M, Raper SE, Kozarsky K, et al: Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994;6:335-341.
4. Hobbs HH, Brown MS, Goldstein JL: Molecular genetics of the LDL receptor gene in familial hypercholeaterolemia. Hum Mutat 1992;1: 445-466.
5. Bild DE, Williams RR, Brewer HB, Herd JA, Pearson TA, Stein E: Identification and management of heterozygous familial hypercholesterolemia: Summary and recommendations from an NHLBI workshop. Am J Cardiol 1993; 72:1D-5D.
6. Chowdhury JR, Grossman M, Gupta S, Chowdhury NR, Baker JR Jr, Wilson JM: Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science 1991;254:1802-1805.
7. Roberts HR: Molecular biology of hemophilia B. Thromb Haemost 1993;70.1-9.
8. Kay MA, Rothenberg S, Landen CN, et al: In vivo gene therapy of hemophilia B: Sustained partial correction in factor IX-deficient dogs. Science 1993;262:117-119.
9. Wu GY, Wu CH: Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense ohgonucleotides. J Biol Chem 1992; 267:12436-12439
10. Offensperger WB, Offensperger S, Walter E, et al: In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. Embo J 1993;12:1257-1262.
11. Moulds C, Lewis JG, Froehler BC, et al: Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides. Biochemistry 1995; 34:5044-5033.
12. Wagner RW: The state of the art in antisense research. Nat Med 1995;1:1116-1118.
13. Huber BE, Richards CA, Austin EA: Virusdirected enzyme/prodrug therapy (VDEPT). Selectively engineering drug sensitivity into tumors. Ann NY Acad Sci 1994;716:104-114.
14. Huber BE, Richards CA, Krenitsky TA: Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy. Proc Natl Acad Sci USA 1991;88:8039-8043.
15. Kaneko S, Hallenbeck P, Kotarn T, et al: Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 1995;55.5283-5287.
16. Hurford RK Jr, Dranoff G, Mulligan RC, Tepper RI: Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat Genet 1995; 10:430-435.
17. Chen SH, Chan XH, Wang Y, et al: Combination gene therapy for liver metastasis of colon carcinoma m vivo. Proc Natl Acad Sci USA 1995;92:2577-2581.
18. Choo Y, Sanchez-Garcia I, Klug A: In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature 1994;372:642-645.
19. Coffin JM: Retroviridae and their replication; in Fields BN, Knipe DM, et al (eds): Fundamental Virology, ed 2. New York, Raven, 1991, pp 645-708.
20. Mann R, Mulligan RC, Baltimore D: Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983;33:153-159.
21. Goff SP, Shenk T: Sleeping with the enemy: Viruses as gene transfer agents. Curr Opin Genet Dev 1993;3:71-73.
22. Goff SP: Genetics of retroviral integration. Annu Rev Genet 1992;26:527-544.
23. Whitcomb JM, Hughes SH: Retroviral reverse transcription and integration: Progress and problems. Annu Rev Cell Biol 1992;8:275-306.
24. Miller DG, Adam MA, Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990;10:4239-4242.
25. Boris-Lawrie KA, Temin HM: Recent advances in retrovirus vector technology. Curr Opin Genet Dev 1992;3:102-109.
26. Miller AD: Retroviral vectors. Curr Top Microbiol Immunol 1992;158:1-24.
27. Russell DW, Miller AD, Alexander IE: Adenoassociated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci USA 1994;91:8915-8919.
28. Kay MA, Ponder KP, Woo SL: Human gene therapy: Present and future. Breast Cancer Res Treat 1992;21:83-93.
29. Graham FL, Prevec L: Adenovirus-based expression vectors and recombinant vaccines. Biotechnology 1992;20:363-390.
30. Herz J, Gerard RD: Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993; 90:2812-2816.
31. Jaffe HA, Danel C, Longenecker G, et al: Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1992;1: 372-378.
32. Kay MA, Landen CN, Rothenberg SR, et al: In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994;91:2353-2357.
33. Yang Y, Ertl HC, Wilson JM: MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994;1:433-442.
34. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM: Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-4411.
35. Yang Y, Li Q, Ertl HC, Wilson JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995;69:2004-2015.
36. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM: Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995;92: 1401-1405.
37. Smith TA, Mehaffey MG, Kayda DB, et al: Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993;5:397-402.
38. Fang B, Eisensmith RC, Wang H, et al: Gene therapy for hemophilia B: Host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995;6:1039-1044.
39. Berns KI, Linden RM: The cryptic life style of adeno-associated virus. Bioessays 1995;17: 237-245.
40. Samulski RJ, Zhu X, Xiao X, et al: Targeted integration of adeno-associated virus (AAV) into human chromosome 19. Embo J 1991;10: 3941-3950.
41. Samulski RJ: Adeno-associated virus: Integration at a specific chromosomal locus. Curr Opin Genet Dev 1993;3:74-80.
42. Kotin RM, Siniscalco M, Samulski RJ, et al: Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990;87:2211-2215.
43. Weitzman MD, Kyostio SR, Kotin RM, Owens RA: Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA 1994;91:5808-5812.
44. Flotte TR, Carter BJ, Adeno-associated virus vectors for gene therapy. Gene Ther 1995;2: 357-362.
45. Lu B, Gupta S, Federoff H: Ex vivo hepatic gene transfer in mouse using a defective herpes simplex virus-1 vector. Hepatology 1995;21: 752-759.
46. Fong Y, Feferoff HJ, Brownlee M, Bramberg D, Blumgart LH, Brennan MF: Rapid and efficient gene transfer in human hepatocytes by herpes viral vectors. Hepatology 1995;22:723-729.
47. Chang C, Ganem D, Lavine J: Foreign gene delivery and expression in hepatocytes using a hepatitis B vector. Hepatology 1991;14:124A.
48. Horwich AL, Furtak K, Pugh J, Summers J: Synthesis of hepadnavirus particles that contain replication-defective duck hepatitis B virus genomes in cultured HuH7 cells. J Virol 1990;64:642-650.
49. Stockert RJ: The asialoglycoprotein receptor: Relationships between structure, function, and expression. Physiol Rev 1995l75:591-609.
50. Curiel DT: Adenovirus facilitation of molecular conjugate-mediated gene transfer. Prog Med Virol 1993;40:1-18.
51. Chowdhury NR, Wu CH, Wu GY, Yemeni PC, Bommineni VR, Chowdhury JR: Fate of DNA targeted to the liver by asialoglycoprotein receptor-mediated endocytosis in vivo: Prolonged persistence in cytoplasmic vesicles after partial hepatectomy. J Biol Chem 1993;268: 11265-11271.
52. Cotton M, Langle-Rouault F, Kirlappos H, et al: Transferrin-polycation-mediated introduction of DNA into human leukemic cells: Stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels. Proc Natl Acad Sci USA 1990;87:4033-4037.
53. Greber UF, Willetts M, Webster P, Helinus A: Stepwise dismantling of adenovirus 2 during entry into cells. Cell 1993;75:477-486.
54. Cotten M, Wagner E, Zatloukal K, Phillips S, Curiel DT, Birnstiel ML: High-efficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosomedisruption activity of defective or chemically inactivated adenovirus particles. Proc Natl Acad Sci USA 1992;89:6094-6098.
55. Cristiano RJ, Smith LC, Woo SL: Hepatic gene therapy Adenovirus enhancement of receptormediated gene delivery and expression in primary hepatocytes. Proc Natl Acad Sci USA 1993;90:2122-2126.
56. Cristiano RJ, Smith LC, Kay MA, Brinkley BR. Woo SL: Hepatic gene therapy: Efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci USA 1993;90: 11548-11552.
57. Wagner E, Zatloukal K, Cotton M. et al: Coupling of adenovirus to transferrin-polylysine/ DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci USA 1992;89: 6099-6103.
58. Wu GY, Wu CH: Receptor-mediated gene delivery and expression in vivo. J Biol Chem 1988;263:14621-14624.
59. Wilson JM, Grossman M, Wu CH, Chowdhury NR, Wu GY: Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits. J Biol Chem 1992;267:963-967.
60. Ferkol T, Lindberg GL, Chen J, et al: Regulation of the phosphoenolpyruvate carboxykinase/human factor IX gene introduced into the livers of adult rats by receptor-mediated gene transfer. Faseb J 1993;7:1081-1091.
61. Farhood H, Gao X, Son K, et al: Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Ann NY Acad Sci 1994; 716:23-34.
62. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ: Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 1995;270:8997-9007.
63. Kaneda Y, Iwai K, Uchida T: Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science 1989;243:375-378.
64. Chonn A, Cullis PR: Recent advances in liposomal drug-delivery systems. Curr Opin Biotechnol 1995;6:698-708.
65. Salmons B, Gunzburg WH: Targeting of retroviral vectors for gene therapy. Hum Gene Ther 1993;4:129-141.
66. Somia NV, Zoppe M, Verma IM: Generation of targeted retroviral vectors by using singlechain variable fragment: An approach to in vivo gene delivery. Proc Natl Acad Sci USA 1995;92:7570-7574.
67. Russell SJ, Hawkins RE, Winter G: Retroviral vectors displaying functional antibody fragments Nucleic Acids Res 1993;21:1081-1085.
68. Kasahra N, Dozy A, Kan YW: Tissue-specific targeting of retroviral vectors through ligandreceptor interactions. Science 1994;266:1373-1376.
69. Valsesia-Wittmann S, Drynda A, Deleage G, et al: Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J Virol 1994; 68:4609-4619.
70. Roux P, Jcanteur P, Piechaczyk M: A versatile and potentially general approach to the targeting of specific cell types by retroviruses: Application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses. Proc Natl Acad Sci USA 1989;86:9079-9083.
71. Miller N, Vile R: Targeted vectors for gene therapy. Faseb J 1995;9:190-199.
72. Chu TH, Martinez I, Sheay WC, Dornburg R: Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene Ther 1994;1:292-299.
73. Chu TH, Dornburg R: Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer J Virol 1995;69:2659-2663
74. Rother RP, Squinto SP, Mason JM, Rollins SA: Protection of retroviral vector particles in human blood through complement inhibition. Hum Gene Ther 1995;6:429-435.
75. Rother RP, Fodor WL, Springhorn JP, et al: A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. J Exp Med 1995;182: 1345-1355.
76. Lieber A, Pceters MJ, Gown A, Perkins J, Kay MA: A modified urokinase plasminogen activator induces liver regeneration without bleeding. Hum Gene Ther 1995;6:1029-1037.
77. Lieber A, Vrancken Peeters MJ, Meuse L, Fausto N, Perkins J, Kay MA: Adenovirusmediated urokinase gene transfer induces liver regeneration and allows for efficient retrovirus transduction of hepatocytes in vivo. Proc Natl Acad Sci USA 1995;92:6210-6214.
78. Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM: Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994;7:362-369.
79. Engelhardt JF, Ye X, Doranz B, Wilson JM: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994;91:6196-6200.
80. Mitani K, Graham FL, Caskey CT, Kochanek S: Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vectors. Proc Natl Acad Sci USA 1995;92: 3854-3858.
81. Wold WS, Gooding LR: Region E3 of adenovirus: A cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology 1991;184:1-8.
82. Mullbacher A: Viral escape from immune recognition: Multiple strategies of adenoviruses. Immunol Cell Biol 1992;70:59-63.
83. Lee MG, Abina MA, Haddada H, Perricaudet M: The constitutive expression of the immunomodulatory gp19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther 1995;2:256-262.
84. Hermiston TW, Tripp RA, Sparer T, Gooding LR. Wold WS: Deletion mutation analysis of the adenovirus type 2 E3-gp19K protein: Identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes. J Virol 1993;67:5289-5298.
85. Yang Y, Trinchieri G, Wilson JM: Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1995;1:890-893.
86. Wilson C, Kay MA: Immunomodulation to enhance gene therapy Nat Med 1995;1:887-889.
87. Kay MA, Holterman AX, Meuse L, et al: Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995;11:191-197.
88. Anton M, Graham FL: Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: A molecular switch for control of gene expression. J Virol 1995;69:4600-4606.